PHIO Stock Catalyst: Phio Pharmaceuticals Corp. Announces Pathology Results in Third Dose Cohort of Skin Cancer Clinical Trial

May 6, 2025 · 7:45pm ET

Company revealed findings from the INTASYL PH-762 trial.

Max move

+54.3%

High of day $2.67

Sparker timei

7:45pm ET

PHIO · May 6, 2025

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

Phio Pharmaceuticals Corp. (PHIO) announced pathology results from the third dose cohort of their INTASYL PH-762 skin cancer clinical trial. The announcement was made to provide updated information on the trial's progress.

The trial is evaluating the safety and efficacy of the company's INTASYL technology in treating skin cancer. Specific data from the third dose cohort were disclosed, though detailed results are pending further analysis.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time PHIO sparks.

Download Sniper App →

Catch the next PHIO-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →